Tasly Capital
Beijing, Beijingtasly.com
Overview
Tasly Capital is the corporate venture capital arm of Tasly Holding Group, established in 2008. Based in Beijing, China, the firm actively invests in the healthcare sector, with a focus on areas such as Oncology, Healthcare IT, and Diabetes. Its investment portfolio includes companies in China, Canada, and the United States.
Portfolio Companies
6
Website
tasly.comInvestments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Hengsai Biotechnology | Dec 2025 | Strategic | Lead |
| Shanghai UniXell Biotechnology | Apr 2024 | Series A | Lead |
| Horimed | Mar 2024 | Series C | Lead |
| Eureka Bio | Feb 2024 | Series B Extension | Co-investor |
| Bobang Fangzhou Medical Technology | May 2021 | Series A | Co-investor |
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.